Kumaramanickavel Govindasamy, Ramprasad Vedam Lakshmi, Sripriya Sarangapani, Upadyay Neelam Kumari, Paul Pradeep George, Sharma Tarun
Department of Genetics and Molecular Biology, Vision Research Foundation, Sankara Nethralaya, 18, College Road, Chennai-600 006, India. drgkkm.sankaranethralaya.org
J Diabetes Complications. 2002 Nov-Dec;16(6):391-4. doi: 10.1016/s1056-8727(02)00187-3.
AIM/HYPOTHESIS: The binding of advanced glycation end products (AGE) to the receptor induces cellular oxidative stress and vascular dysfunction and this is implicated in the pathogenesis of diabetic retinopathy (DR). This study aims to investigate the frequency of Gly82Ser polymorphism in exon 3 of the receptor for AGE (RAGE) gene and its association with DR in Asian Indian patients who have type II diabetes.
200 Asian Indian patients with at least 15-year duration of type II diabetes were identified. This group included (1) 100 patients with retinopathy (DR) and (2) 100 patients without retinopathy (DNR). Fifty unrelated healthy controls (CT) were also included in the study. Genotype frequencies of Gly82Ser polymorphism were studied by polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism analysis using AluI enzyme. Later, the nucleotide change was confirmed by DNA sequencing.
The frequency of the Ser82 allele was significantly higher, 18% in the DNR group compared to 7% in the DR group (P=.03). The same genotype was 2% in the CT group.
CONCLUSION/INTERPRETATION: Our result suggests that Ser82 allele in the receptor for AGE gene is a low-risk allele for developing DR in Asian Indian patients who have type II diabetes.
目的/假设:晚期糖基化终末产物(AGE)与受体的结合会诱导细胞氧化应激和血管功能障碍,这与糖尿病视网膜病变(DR)的发病机制有关。本研究旨在调查亚洲印度裔II型糖尿病患者中AGE受体(RAGE)基因第3外显子Gly82Ser多态性的频率及其与DR的关联。
确定了200名病程至少15年的亚洲印度裔II型糖尿病患者。该组包括(1)100名患有视网膜病变(DR)的患者和(2)100名无视网膜病变(DNR)的患者。50名无关的健康对照者(CT)也纳入了研究。通过聚合酶链反应(PCR)扩增和使用AluI酶的限制性片段长度多态性分析研究Gly82Ser多态性的基因型频率。随后,通过DNA测序确认核苷酸变化。
Ser82等位基因的频率在DNR组中显著更高,为18%,而在DR组中为7%(P = 0.03)。同一基因型在CT组中为2%。
结论/解读:我们的结果表明,在亚洲印度裔II型糖尿病患者中,AGE基因受体中的Ser82等位基因是发生DR的低风险等位基因。